Leukotriene B4 antagonist compound
US9187411B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jan 4, 2013 |
| Grant date | Nov 17, 2015 |
| Priority date | — |
| Expiry date | Feb 3, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P19/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The present invention further provides methods for treating abdominal aortic aneurysm or atherosclerosis comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula (I) or pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.